Compare EM & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EM | ABSI |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 577.4M |
| IPO Year | 2021 | 2021 |
| Metric | EM | ABSI |
|---|---|---|
| Price | $1.33 | $3.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.25 | ★ $7.78 |
| AVG Volume (30 Days) | 699.5K | ★ 4.1M |
| Earning Date | 11-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $259,541,587.00 | $2,815,000.00 |
| Revenue This Year | $3.30 | $10.72 |
| Revenue Next Year | $5.26 | $437.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.68 | $2.01 |
| 52 Week High | $1.46 | $6.33 |
| Indicator | EM | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 49.09 |
| Support Level | $1.33 | $3.35 |
| Resistance Level | $1.37 | $4.06 |
| Average True Range (ATR) | 0.03 | 0.29 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 10.65 | 39.07 |
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.